Chronic Kidney Disease Summary
The Chronic Kidney Disease (CKD) market in the United States was estimated at approximately USD 2,824 million in 2023 and is projected to demonstrate sustained growth throughout the forecast period. The US exhibited the highest CKD prevalence among the 7MM, with an estimated 40 million cases in 2023, expected to increase by 2034. Gender-specific prevalence in 2023 accounted for approximately 2 million males and 3 million females. Current CKD management—encompassing erythropoiesis-stimulating agents (ESAs), ACE inhibitors, ARBs, antidiabetic therapies, secondary hyperparathyroidism (SHPT) treatments, and urate-lowering agents—contributed to a 7MM market size of USD 5,479 million in 2023, with anticipated expansion driven by forthcoming therapeutic launches through 2034. Notably, Boehringer Ingelheim’s BI-690517, a selective aldosterone synthase inhibitor, achieved a 39.5% reduction in albuminuria over 14 weeks in combination with empagliflozin in a Phase II trial, representing the inaugural study of this class atop standard of care. These findings, presented at ASN Kidney Week 2023, underscore the evolving CKD treatment paradigm. Additionally, Japan’s CKD therapeutics market was valued at USD 1,402 million in 2023 and is projected to register significant growth by 2034.
DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Forecast-2034” report provides a comprehensive analysis of chronic kidney disease (CKD), encompassing historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The CKD market is anticipated to experience substantial growth over the forecast period, driven by the rising prevalence of the disease and increasing awareness. Additionally, the introduction of multiple pipeline therapies across various development stages is expected to significantly reshape the market landscape and influence future CKD treatment paradigms.
To know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
Some of the key facts of the Chronic Kidney Disease Market Report:
- The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In August 2025, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for UNI-494 to treat Chronic Kidney Disease (CKD). This patent follows the issuance of an earlier method of use patent for the treatment of Acute Kidney Injury with UNI-494.
- In July 2025, ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced confirmation of alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. Rilparencel is an autologous cellular therapy that received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and currently is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
- In March 2025, the FDA broadened the approval of Furoscix (furosemide injection) to include the treatment of edema in adults with chronic kidney disease (CKD), including those with nephrotic syndrome. The expanded indication, developed by scPharmaceuticals, Inc., is expected to become available by April 2025, following the agency's acceptance of the supplemental new drug application in July 2024.
- In January 2025, the FDA approved a new indication for semaglutide, allowing its use to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD, as announced by Novo Nordisk.
- The Chronic Kidney Disease therapeutics market size in the US was approximately USD 2,824 million in 2023 and is expected to grow further during the forecast period.
- In 2023, the United Kingdom had the largest Chronic Kidney Disease market size among the EU countries, with nearly USD 421 million, while Italy recorded the smallest market size at approximately USD 132 million.
- The Chronic Kidney Disease therapeutics market size in Japan was estimated at around USD 1,402 million in 2023.
- According to DelveInsight's analysis, the total diagnosed prevalent cases of Chronic Kidney Disease in the 7MM were approximately 16 million in 2023.
- In 2023, the United States held the largest Chronic Kidney Disease market size among the 7MM, valued at around USD 2,824 million, with projections indicating further growth by 2034.
- In 2023, the United States reported the highest prevalence of Chronic Kidney Disease among the 7MM, with approximately 40 million cases, and this number is projected to grow by 2034.
- The Chronic Kidney Disease market in 2023, valued at USD 5,479 million across the 7MM, primarily consists of erythropoietin-stimulating agents (ESAs), ACE inhibitors, angiotensin receptor blockers (ARBs), antidiabetic medications, treatments for secondary hyperparathyroidism (SHPT), and urate-lowering therapies. The market is anticipated to expand further with the introduction of emerging therapies during the forecast period (2024-2034).
- In 2023, Japan's Chronic Kidney Disease market size was valued at USD 1,402 million, with projections indicating substantial growth at a notable CAGR by 2034.
- In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of Chronic Kidney Disease among European countries, with around 2 million cases, followed by Germany with approximately 1 million cases. Italy, on the other hand, had the lowest prevalent population, totaling 731 thousand cases.
- In 2023, Japan reported nearly 3 million total diagnosed prevalent cases of Chronic Kidney Disease, representing about 22% of the total cases across the 7MM.
- DelveInsight's analysis shows that in the EU4 and the UK, more females are impacted than males, with approximately 3.55 million female cases and 3.4 million male cases in 2023.
- Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others
- Chronic Kidney Disease Therapies: Ocedurenone (KBP-5074), BI 690517 + Empagliflozin, and others.
- The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)
Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body. The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.
Get a Free sample for the Chronic Kidney Disease Market Report to know more about emerging therapies, fda approvals and growth factors @ Chronic Kidney Disease Treatment Market
Chronic Kidney Disease Epidemiology
According to DelveInsight’s analysis, the total diagnosed prevalent cases of Chronic Kidney Disease (CKD) in the 7MM were estimated at approximately 16 million in 2023. The United States accounted for the highest number of diagnosed cases with 5 million, which is expected to increase over the forecast period. Within Europe, the United Kingdom recorded the highest diagnosed CKD prevalence at around 2 million cases, followed by Germany with ~1 million cases, while Italy had the lowest prevalence at 731,000 cases. In Japan, total diagnosed cases were estimated at 3 million, representing roughly 22% of the 7MM total. By disease severity, Stage 3 CKD affected the largest population in the US, totaling ~2.94 million cases in 2023. Additionally, DelveInsight’s findings indicate that in the EU4 and the UK, females were slightly more affected than males, with 3.55 million female cases versus 3.4 million male cases in 2023.
Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Prevalence of Chronic Kidney Disease
- Prevalent Cases of Chronic Kidney Disease by severity
- Gender-specific Prevalence of Chronic Kidney Disease
- Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease
Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Patient Pool Forecast
Chronic Kidney Disease Market Outlook
The US CKD therapeutics market was valued at ~USD 2,824 million in 2023, representing the largest share (~52%) of the 7MM market. Among European countries, the UK market was highest at USD 421 million, while Italy recorded the lowest at ~USD 132 million. The Japanese CKD therapeutics market was estimated at USD 1,402 million in 2023 and is projected to expand further during the forecast period.
Chronic Kidney Disease (CKD) management primarily aims to slow disease progression, control symptoms, and prevent associated complications. Lifestyle interventions form the cornerstone of therapy, encompassing dietary modifications, structured physical activity, and smoking cessation. Patients are typically advised to restrict salt, potassium, and protein intake to reduce renal burden.
Pharmacological strategies are critical in CKD management. ACE inhibitors and angiotensin II receptor blockers (ARBs) are commonly prescribed to control hypertension and mitigate proteinuria, thereby decelerating disease progression. Statins are employed to manage hyperlipidemia and reduce cardiovascular risks, which are significantly elevated in CKD patients. Glycemic control in diabetic CKD is achieved using agents such as metformin and SGLT2 inhibitors, which confer renal protective effects. Erythropoiesis-stimulating agents (ESAs) and iron supplementation address CKD-associated anemia.
In advanced stages, renal replacement therapies such as hemodialysis or peritoneal dialysis are indicated, while kidney transplantation remains the definitive treatment for end-stage renal disease (ESRD), necessitating lifelong immunosuppression. Management also focuses on controlling comorbidities including hypertension, hyperglycemia, and dyslipidemia. Regular monitoring and timely interventions are essential for improving patient outcomes and quality of life.
Chronic Kidney Disease Therapies and Key Companies
- TRC101 (Veverimer): Tricida
- Tolvaptan: Otsuka Pharmaceuticals
- AZD5718: AstraZeneca
- KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals Inc.
- INVOKANA (canagliflozin): Janssen Research & Development, LLC
- Ocedurenone (KBP-5074): KBP Biosciences
- BI 690517 + Empagliflozin: Novo Nordisk A/S
- And many others
To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications
Chronic Kidney Disease Market Drivers
- Rising CKD Prevalence – Increasing incidence of CKD worldwide, particularly in the US, EU, and Japan, drives demand for therapies.
- Aging Population – Higher susceptibility to CKD with advancing age contributes to market growth.
- Comorbidities – Prevalence of diabetes, hypertension, and cardiovascular disorders increases CKD risk, expanding the patient pool.
- Innovation in Therapeutics – Introduction of novel agents such as selective aldosterone synthase inhibitors, SGLT2 inhibitors, and improved ESAs enhances treatment options.
- Rising Awareness and Screening – Increased disease awareness and early diagnosis programs support early intervention, boosting market uptake.
- Supportive Reimbursement Policies – Insurance coverage for CKD treatments and renal replacement therapies encourages patient access and adherence.
Chronic Kidney Disease Market Barriers
- High Treatment Costs – Advanced therapies and dialysis procedures can be cost-prohibitive, limiting accessibility.
- Complex Disease Management – CKD often requires multifactorial management, including comorbid conditions, complicating therapy adherence.
- Side Effects and Safety Concerns – Long-term use of drugs such as ESAs, ARBs, and immunosuppressants can lead to adverse events.
- Limited Access in Emerging Markets – Inadequate healthcare infrastructure and lack of screening programs restrict market penetration.
- Slow Adoption of Novel Therapies – Regulatory hurdles and clinician conservatism may delay uptake of innovative CKD treatments.
Scope of the Chronic Kidney Disease Market Report
- Study Period: 2020-2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
- Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
- Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
- Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement
Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Landscape
Table of Contents
1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
